13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q2 2018. See the latest, Q2 2026 →
Reported value
$1.19B
+94% on the quarter before
Positions
17
7 new · 1 sold out
Top 10
96.1%
of the value
Est. gain
−$83.1M
on stocks held all quarter
Est. return
−14.7%
on those stocks since Q1 2018
Positions as of Jun 30, 2018, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2018. Striped tiles are options.
Largest buys
Since Q1 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Jd Com Inc~$527.9MNew · 0.0% → 44.3%+13,553,474 shares
- DocuSign~$77.4MNew · 0.0% → 6.5%+1,461,106 shares
- Magenta Therapeutics Inc~$45.1MNew · 0.0% → 3.8%+3,339,138 shares
- Forty Seven Inc~$24.7MNew · 0.0% → 2.1%+1,545,966 shares
- Autolus Therapeutics Plc~$19.1MNew · 0.0% → 1.6%+714,072 shares
- Evelo Biosciences Inc~$12.5MNew · 0.0% → 1.1%+1,060,495 shares
- Pluralsight Inc~$2.5MNew · 0.0% → 0.2%+101,442 shares
Largest sells
Since Q1 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Armo Biosciences Inc~$45.4MSold out · 7.4% → 0.0%−1,214,700 shares
- Cloudera Inc~$2.8MCut · 3.7% → 1.0%−206,000 shares
- Denali Therapeutics Inc~$461,374Cut · 1.8% → 0.7%−30,255 shares
Holdings
As of Jun 30, 2018. Changes are in shares against Mar 31, 2018, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jd Com IncSPON ADR CL A · shares New | 44.3% | $527.9M | — | ||||||||
| Arris Intl IncSHS · shares 0% · price −8.0% | 19.9% | $237.2M | −$20.6M | ||||||||
| ZscalerCOM · shares 0% · price +27.4% | 8.4% | $99.7M | +$21.4M | ||||||||
| DocuSignCOM · shares New | 6.5% | $77.4M | — | ||||||||
| Arcus Biosciences IncCOM · shares 0% · price −20.7% | 5.2% | $61.8M | −$16.2M | ||||||||
| Magenta Therapeutics IncCOM · shares New | 3.8% | $45.1M | — | ||||||||
| SnapCL A · shares 0% · price −17.5% | 2.9% | $34.3M | −$7.3M | ||||||||
| Forty Seven IncCOM · shares New | 2.1% | $24.7M | — | ||||||||
| Autolus Therapeutics PlcSPON ADS · shares New | 1.6% | $19.1M | — | ||||||||
| Spero Therapeutics IncCOM · shares 0% · price +2.9% | 1.4% | $16.3M | +$467,000 | ||||||||
| Evelo Biosciences IncCOM · shares New | 1.1% | $12.5M | — | ||||||||
| Cloudera IncCOM · shares −19% · price −36.8% | 0.98% | $11.7M | −$6.8M | ||||||||
| Arsanis IncCOM · shares 0% · price −84.1% | 0.83% | $9.8M | −$52.2M | ||||||||
| Denali Therapeutics IncCOM · shares −5.3% · price −22.6% | 0.69% | $8.2M | −$2.4M | ||||||||
| Pluralsight IncCL A · shares New | 0.21% | $2.5M | — | ||||||||
| BlockCL A · shares 0% · price +25.3% | 0.15% | $1.8M | +$366,000 | ||||||||
| Dropbox IncCL A · shares 0% · price +3.9% | 0.04% | $423,000 | +$16,000 | ||||||||
| Total · 17 positions | 100% | $1.19B | −$83.1M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2018 to Q2 2018: 10 stocks held throughout, down $83.1M (−14.7%).
- Zscaler+$21.4M+27%
- Spero Therapeutics Inc+$467,000+3%
- Block+$366,000+25%
- Dropbox Inc+$16,000+4%
- Cloudera Inc−$6.8M−37%
- Snap−$7.3M−18%
- Arcus Biosciences Inc−$16.2M−21%
- Arris Intl Inc−$20.6M−8%
- Arsanis Inc−$52.2M−84%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |